Alumis completes patient enrollment in global LUMUS Phase 2b trial of ESK-001

Alumis (ALMS) announced the completion of patient enrollment in its global LUMUS Phase 2b trial of ESK-001, a highly selective, next-generation oral tyrosine kinase 2 inhibitor, for the treatment of systemic lupus erythematosus, the most common form of lupus. “Completion of enrollment in our global LUMUS Phase 2b trial for SLE marks a significant milestone for Alumis, and importantly, for the lupus community,” said Martin Babler, President and Chief Executive Officer of Alumis. “This achievement reflects the dedication of our clinical partners, investigators, patients, and the entire Alumis team, positioning us to share topline data in the third quarter of 2026.”